

UTILITY	Attorney Docket No.	2747/1021		
PATENT APPLICATION	First Inventor	Mousa		
TRANSMITTAL	i illie i	ED HEPARIN FRACTIONS AND		
(Only for new nonprovisional applications under 37 CFR 1.53(b))		USE IN INHIBITING		
7,7	ANGIO	GENESIS EV138584940US		
	Express Mail Label N	10.		
APPLICATION ELEMENTS	ADDRESS TO	Mail Stop Patent Application Commissioner for Patents		
See MPEP chapter 600 concerning utility patent application contents.		P.O. Box 1450		
1. E Fee Transmittal Form (e.g., PTO/SB/17)	7 □ CD-RO	Alexandria, Virginia 22313-1450 M or CD-R in duplicate, large table or		
(Submit an original and a duplicate for fee processing)	Comput	er Program (Appendix)		
2. Applicant claims small entity status. See 37 CFR 1.27.		and/or Amino Acid Sequence Submission le, all necessary)		
3. E Specification [Total Pages 42]		puter Readable Form (CRF)		
(preferred arrangement set forth below) - Descriptive title of the invention	 b. Specifica 	tion Sequence Listing on:		
 Cross Reference to Related Applications (if applicable) 		CD-ROM or CD-R (2 copies; or		
- Statement Regarding Fed sponsored R & D (if applicable)	ii. □			
 Reference to sequence listing, a table, or a computer program listing appendix (if applicable) 		ments verifying identity of above copies MPANYING APPLICATION PARTS		
- Background of the Invention	Accor	MITANTING AFFLICATION PARTS		
 Brief Summary of the Invention Brief Description of the Drawings (if filed) 		ment Papers (cover sheet & document(s))		
- Detailed Description		R 3.73(b) Statement Power of		
- Claim(s)		there is an assignee) Attorney Translation Document (if applicable)		
- Abstract of the Disclosure		ation Disclosure		
4. Drawing(s) (35 U.S.C. 113) [Total Sheets 5] 5. Oath or Declaration [Total Pages 2]		ent (IDS)/PTO-1449 Citations		
a. Newly executed (original or copy)		inary Amendment		
b. 🗷 Unsigned		Receipt Postcard (MPEP 503)		
c. D Copy from a prior application (37 CFR 1.63(d))		(Should be specifically itemized) 15. □ Certified Copy of Priority Document(s)		
(for continuation/divisional with Box 18 completed) i. □ DELETION OF INVENTOR(S)		(if foreign priority is claimed)		
i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s)		blication request under 35 U.S.C.		
named in the prior application, see 37 CFR		(2)(B)(i). Applicant must attach form B/35 or its equivalent.		
1.63(d)(2) and 1.33(b) 6.		- t		
• •				
18. If a CONTINUING APPLICATION, check appropriate box, and su or in an Application Data Sheet under 37 CFR 1.76:	pply the requisite infor	mation below and in a preliminary amendment,		
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP)	of prior applica	ation No.:/		
Prior application information: Examiner		Unit:		
For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of	-			
Box 5b, is considered a part of the disclosure of the accompanying continuation	or divisional application	and is hereby incorporated by reference. The		
incorporation can only be relied upon when a portion has been inadvertently on		application parts.		
19. CORRESPONDI	ENCE ADDRESS			
Customer Number or Bar Code Label		or Correspondence address below		
Name Nixon Peabody LLP				
Clinton Square, P.O. Box 31051 Address				
City Rochester State N	Y	Zip Code 14603-1051		
	85) 263-1672	Fax (585) 263-1600		
Name (Print/Type) Georgia Evans Registration No	(Attornov/Agort)	44.507		
Name (Print/Type) Georgia Evans Registration No	o. (Attorney/Agent)	44,597		
Signature Deuria wan		September 19,200		
15: 1011010 /1-00		1 Ventruber 14 doc		

UTILITY	Attorney Docket No. 2747/1021				
PATENT APPLICATION	First Inventor -Mousa				
TRANSMITTAL	Title OXIDIZED HEPARIN FRACTIONS AND				
(Only for new nonprovisional applications under 37 CFR 1.53(b))	THEIR USE IN INHIBITING				
(only) or now non-pro-section approximately	ANGIOGENESIS EV138584940US				
	Express Mail Label No. Mail Stop Patent Application				
APPLICATION ELEMENTS	ADDRESS TO: Commissioner for Patents				
See MPEP chapter 600 concerning utility patent application contents.	P.O. Box 1450 Alexandria, Virginia 22313-1450				
1. E Fee Transmittal Form (e.g., PTO/SB/17)	7. CD-ROM or CD-R in duplicate, large table or				
(Submit an original and a duplicate for fee processing) 2. Applicant claims small entity status.	Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission				
See 37 CFR 1.27.	(if applicable, all necessary)				
3. Specification [Total Pages 42] (preferred arrangement set forth below)	a. Computer Readable Form (CRF)				
 Descriptive title of the invention 	b. Specification Sequence Listing on: i.				
- Cross Reference to Related Applications (if applicable)	ii. paper				
 Statement Regarding Fed sponsored R & D (if applicable) Reference to sequence listing, a table, 	c. Statements verifying identity of above copies				
or a computer program listing appendix (if applicable)	ACCOMPANYING APPLICATION PARTS				
 Background of the Invention Brief Summary of the Invention 	9. Assignment Papers (cover sheet & document(s))				
- Brief Description of the Drawings (if filed)	10. ☐ 37 CFR 3.73(b) Statement ☐ Power of				
 Detailed Description Claim(s) 	(when there is an assignee) Attorney				
- Abstract of the Disclosure	11. English Translation Document (if applicable)				
4. E Drawing(s) (35 U.S.C. 113) [Total Sheets 5]	12. Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations				
5. Oath or Declaration [Total Pages 2]	13. Preliminary Amendment				
a. Newly executed (original or copy) b. E Unsigned	14. E Return Receipt Postcard (MPEP 503)				
c. \square Copy from a prior application (37 CFR 1.63(d))	(Should be specifically itemized)				
(for continuation/divisional with Box 18 completed)	15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)				
i. DELETION OF INVENTOR(S)	16. Nonpublication request under 35 U.S.C.				
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR	122(b)(2)(B)(i). Applicant must attach form				
1.63(d)(2) and 1.33(b)	PTO/SB/35 or its equivalent. 17. Other:				
6. Application Data Sheet. See 37 CFR 1.76					
18. If a CONTINUING APPLICATION, check appropriate box, and so or in an Application Data Sheet under 37 CFR 1.76:	upply the requisite information below and in a preliminary amendment,				
Continuation Divisional Continuation-in-part (CIP)	of prior application No.:/				
Prior application information: Examiner	Group / Art Unit:				
For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of	the prior application, from which an oath or declaration is supplied under				
Box 5b, is considered a part of the disclosure of the accompanying continuation incorporation can only be relied upon when a portion has been inadvertently of					
19. CORRESPOND					
☐ Customer Number or Bar Code Label or 区 Correspondence address below					
Name Nixon Peabody LLP					
Clinton Square, P.O. Box 31051 Address					
City Rochester State N	Y Zip Code 14603-1051				
	85) 263-1672 Fax (585) 263-1600				
Name (Print/Type) Georgia Evans Registration N	o. (Attorney/Agent) 44,597				
Signature Leuria wan	September 19,200				

3

FEE TRANSMITTAL FOR FY 2003

Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 723

Complete if Known				
Application Number	To Be Assigned			
Filing Date	Herewith			
First Named Inventor	Mousa			
Examiner Name	To Be Assigned			
Art Unit	To Be Assigned			
Attorney Docket No.	2747/1021			

METHOD OF	PAYMENT (check all that apply)	FEE CALCULATION (continued)							
	Card Money Other None	3. ADDITIONAL FEES							
Deposit Account:		Large Fee	rge Entity Small Entity e Fee Fee Fee Fee Description			intian			
Account 14-113	38	Code	(\$)	Code			ree Desci	tption	
Number		1051	130	2051	65	-	e - late filing fee		
		1052	50	2052	25	Surcharge sheet	e - late provisiona	ll filing fee or cover	
Deposit		1053	130	1053	130		lish specification		-
Account Nixon Name	Peabody LLP	1812	2,520	1812	2,520	For filing	a request for ex i	parte reexamination	
Name	, , , , , , , , , , , , , , , , , , , ,	1804	920*	1804	920*	Requesting publication of SIR prior to Examiner			
The Commissioner is au	thorized to: (check all that apply)				,20	action			
Charge fee(s) indicated	l below Credit any overpayments	1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner			
Charge any additional	fee(s)	1251	110	2251	55	action Extension	for reply within	first month	
	below, except for the filing fee	1252	410	2252	205	Extension for reply within second month			
to the above-identified depos		1253	930	2253	465				
FE	E CALCULATION	1253	1,450	2254	725		Extension for reply within third month		
	E CALCULATION	4				Extension for reply within fourth month			
1. BASIC FILING FEE	***	1255	1,970	2255	985	Extension for reply within fifth month		fifth month	
Large Entity Small E Fee Fee Fee	ntity Fee Fee Description	1401	320	2401	160	Notice of	Appeal		
	(S) Fee Paid	1402	320	2402	160	Filing a b	rief in support of	an appeal	
		1403	280	2403	140	Request for	or oral hearing	Ì	
1001 750 2001	375 Utility filing fee 375	1451	1,510	1451	1,510	Petition to	institute a public	use proceeding	
1002 330 2002	165 Design filing fee	1452	110	2452	55	Petition to	revive – unavoio	iable	
1003 520 2003	260 Plant filing fee	1453	1,300	2453	650	Petition to revive – unintentional			
1004 750 2004	375 Reissue filing fee	1501	1,300	2501	650	Utility issue fee (or reissue)			
1005 160 2005	80 Provisional filing fee	1502	470	2502	235	Design iss		ĺ	
1003 100 2003	ov Provisional fining fee	1503	630	2503	315	Plant issue		•	
s	SUBTOTAL (1) (S) 375	1460	130	1460	130		o the Commission	ner	
•	(\$) 375		-						
2. EXTRA CLAIM F	EES FOR UTILITY AND REISSUE	1807 1806	50 180	1807 1806	50 180		g fee under 37 CF		·
2. EATRA CLAIM F	Fee from	8021	40	8021	40		on of Information	gnment per property	
	Extra Claims below Fee Paid	0021	70	0021	40		nber of properties		
Total Claims 54 -20	**= 34 X 9.00 = 306	1809	750	2809	375		bmission after fir	nal rejection	
Independent 4 -3*	$* = \begin{bmatrix} 1 \\ X \end{bmatrix} X \begin{bmatrix} 42.00 \\ = \end{bmatrix} = \begin{bmatrix} 42 \\ \end{bmatrix}$	1810	750	2810	375	(37 CFR I		on to be examined	
Claims		1		2010	3.3	(37 CFR 1		on to be examined	1
Multiple Dependent	X = 0	1801	750	2801	375	Request fo	or Continued Exam	mination (RCE)	
Large Entity Small E	ntity	1802	900	1802	900	Dagwart fo	or avaaditad avam	ination of a design	
	Fee Fee Description	1002	200	1002	300	application		illiation of a design	
Code (\$) Code (S)	Other f	ee (specif	ý)				Ī	
1202 18 2202	9 Claims in excess of 20						_		
1201 84 2201	Independent claims in excess of 3	[7
1203 280 2203 1	40 Multiple dependent claim, if not paid	*Reduc	ced by Ba	sic Filin	g Fee Paid		SUBTOTAL	(3) (\$) 0	
	42 ** Reissue independent claims over								
.20. 01 2201	original patent	CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)]							
1205 18 2205	9 ** Reissue claims in excess of 20 and over original patent								
	<u> </u>	deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Mail Stop							
************************	SUBTOTAL (2) (S) 348	Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450							
**or number previously paid, if greater; For Reissues, see above transmitted by facsimile on the date shown below to the United States Patent and					nt and				
Trademark Office at (703)									
	Date Signature								
		Typed or printed name							
SUBMITTED BY Complete (if applicable)									
Name (Print/Type)	Georgia Evans		ation No		14,597		Telephone	(585) 263-1672	
Signature	Dura Han				_		Date	September 19, 2	003

DOCKET NO.:

2747/1021

APPLICANTS:

Shaker A. Mousa

TITLE:

OXIDIZED HEPARIN FRACTIONS AND THEIR USE IN

INHIBITING ANGIOGENESIS

Certificate is attached to the Request and Certification under 35 U.S.C. § 122(b)(2)(b)(i) of the above-named application.

"EXPRESS MAIL" NUMBER:

EV138584940US

DATE OF DEPOSIT:

September 19, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the **Mail Stop Patent Application**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Georgia Evans

(Typed or printed name of person mailing paper or fee)

Signature of person mailing paper or fee)

PATENT

Docket No.: 2747/1021

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Shaker A. Mousa)	Examiner:
11)	To Be Assigned
Serial No.	:	To Be Assigned)	
)	Art Unit:
Cnfrm. No.	:	To Be Assigned)	To Be Assigned
Filed		Herewith)	
riieu	:	Herewitti)	
For	:	OXIDIZED HEPARIN FRACTIONS AND)	
		THEIR USE IN INHIBITING ANGIOGENESIS)	
)	
)	

REQUEST AND CERTIFICATION UNDER 35 U.S.C. § 122(b)(2)(B)(i)

Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Applicants hereby request that the attached application not be published under 35 U.S.C. 122(b).

Applicants certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing.

No fees are believed to be due. However, please charge Deposit Account No. 14-1138 for any additional fees that may be incurred.

Respectfully submitted,

Date: Suprember 19, 2003

Georgia/Evans

Registration No. 44,597

Nixon Peabody LLP Clinton Square, P.O. Box 31051 Rochester, New York 14603 Telephone: (585) 263-1672 Facsimile: (585) 263-1600

B61018.1

PATENT

Docket No.: 2747/1021

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Shaker A. Mousa)	Examiner:
Serial No.	:	To Be Assigned)	To Be Assigned
Cnfrm. No.	:	To Be Assigned)	Art Unit: To Be Assigned
Filed	:	Herewith))	
For	:	OXIDIZED HEPARIN FRACTIONS AND THEIR USE IN INHIBITING ANGIOGENESIS)))	

REQUEST AND CERTIFICATION UNDER 35 U.S.C. § 122(b)(2)(B)(i)

Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Applicants hereby request that the attached application not be published under 35 U.S.C. 122(b).

Applicants certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing.

No fees are believed to be due. However, please charge Deposit Account No. 14-1138 for any additional fees that may be incurred.

Respectfully submitted,

Date: Suprember 19, 2003

Georgia/Evans

Registration No. 44,597

Nixon Peabody LLP

Clinton Square, P.O. Box 31051

Rochester, New York 14603 Telephone: (585) 263-1672

Facsimile: (585) 263-1600

DEINIQ

DOCKET NO.:

2747/1021

APPLICANTS:

Shaker A. Mousa

TITLE:

OXIDIZED HEPARIN FRACTIONS AND THEIR USE IN

INHIBITING ANGIOGENESIS

Certificate is attached to the **Utility Patent Application Transmittal (1 page)** (in duplicate) of the above-named application.

"EXPRESS MAIL" NUMBER:

EV138584940US

DATE OF DEPOSIT:

September 19, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the **Mail Stop Patent Application**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Georgia Evans

(Typed or printed name of person mailing paper or fee)

(Signature of person mailing paper or fee)

DOCKET NO.:

2747/1021

APPLICANTS:

Shaker A. Mousa

TITLE:

OXIDIZED HEPARIN FRACTIONS AND THEIR USE IN

INHIBITING ANGIOGENESIS

Certificate is attached to the Fee Transmittal for FY 2003 (1 page) (in duplicate) of the above-named application.

"EXPRESS MAIL" NUMBER:

EV138584940US

DATE OF DEPOSIT:

September 19, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the **Mail Stop Patent Application**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Georgia Evans

(Typed or printed name of person mailing paper or fee)

Signature of person mailing paper or fee

DOCKET NO.:

2747/1021

APPLICANTS:

Shaker A. Mousa

TITLE:

OXIDIZED HEPARIN FRACTIONS AND THEIR USE IN

INHIBITING ANGIOGENESIS

Certificate is attached to the Patent Application, Including Specification, Claims, and Abstract (42 pages) and UNSIGNED Combined Declaration and Power of Attorney (2 pages) of the above-named application.

"EXPRESS MAIL" NUMBER:

EV138584940US

DATE OF DEPOSIT:

September 19, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the **Mail Stop Patent Application**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Georgia Evans

(Typed or printed name of person mailing paper or fee)

Signature of person mailing paper or fee)

DOCKET NO.:

2747/1021

APPLICANTS:

Shaker A. Mousa

TITLE:

OXIDIZED HEPARIN FRACTIONS AND THEIR USE IN

INHIBITING ANGIOGENESIS

Certificate is attached to the **Five (5) pages of drawings** of the above-named application.

"EXPRESS MAIL" NUMBER:

EV138584940US

DATE OF DEPOSIT:

September 19, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the **Mail Stop Patent Application**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Georgia Evans

(Typed or printed name of person mailing paper or fee)

Signature of person mailing paper or fee